• 1
    Franco M, Cooper RS, Bilal U, et al. Challenges and opportunities for cardiovascular disease prevention. Am J Med. 2011;124:95102.
  • 2
    Maher D, Waswa L, Baisley K, et al. Distribution of hyperglycaemia and related cardiovascular disease risk factors in low-income countries: a cross-sectional population-based survey in rural Uganda. Int J Epidemiol. 2011;40:160171.
  • 3
    Ventura HO, Mehra MR. The growing burden of heart failure: the “syndemic” is reaching Latin America. Am Heart J. 2004;147:386389.
  • 4
    Rubinstein A, Alcocer L, Chagas A. High blood pressure in Latin America: a call to action. Ther Adv Cardiovasc Dis. 2009;3:259285.
  • 5
    Cuevas A, Alvarez V, Carrasco F. Epidemic of metabolic syndrome in Latin America. Curr Opin Endocrinol Diabetes Obes. 2011;18:134138.
  • 6
    Cantú-Brito C, Ruiz-Sandoval JL, Murillo-Bonilla LM, et al. Acute care and one-year outcome of Mexican patients with first-ever acute ischemic stroke: the PREMIER study. Rev Neurol. 2010;51:641649.
  • 7
    Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786.e1786.e10.
  • 8
    Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180189.
  • 9
    Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:13501357.
  • 10
    Gaxiola E, Eng-Ceceña L, Ortiz-Galvén F, et al; Reduction of Atherothrombosis for Continued Health Registry Investigators. Assessment of atherothrombosis and its treatment in Mexico: first-year data of the REACH registry. Clin Cardiol. 2010;33:445451.
  • 11
    Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:11971206.
  • 12
    Alberts MJ, Bhatt DL, Mas JL, et al. Three-year follow-up and event rates in the international Reduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30:23182326.
  • 13
    Meadows TA, Bhatt DL, Cannon CP, et al. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011;86:960967.
  • 14
    Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:18921899.
  • 15
    Murabito JM, Evans JC, Larson MG, et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med. 2003;163: 19391942.
  • 16
    Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:20532061.
  • 17
    Canté-Brito C, Chiquete E, Duarte-Vega M, et al; Multicenter INDAGA Study Investigators. Abnormal ankle-brachial index in the Mexican population with vascular risk [article in Spanish]. Rev Med Inst Mex Seguro Soc. 2011;49: 239246.
  • 18
    Amudha K, Chee KH, Tan KS, et al. Prevalence of peripheral artery disease in urban high-risk Malaysian patients. Int J Clin Pract. 2003;57:369372.
  • 19
    Cacoub PP, Abola MT, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) registry. Atherosclerosis. 2009;204:e86e92.
  • 20
    Sen S, Lynch DR Jr, Kaltsas E, et al. Association of asymptomatic peripheral arterial disease with vascular events in patients with stroke or transient ischemic attack. Stroke. 2009;40: 34723477.
  • 21
    Banerjee A, Fowkes FG, Rothwell PM. Associations between peripheral artery disease and ischemic stroke: implications for primary and secondary prevention. Stroke. 2010;41:21022107.
  • 22
    Vaartjes I, van Dis I, Grobbee DE, et al. The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke. BMC Cardiovasc Disord. 2010;10:57.
  • 23
    Meizels A, Zeitoun DM, Bataille V, et al; the Alliance Project. Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. Arch Cardiovasc Dis. 2010;103:207214.
  • 24
    Sander D, Carolei A, Diehm C, et al. Challenges to the management of high-risk stroke patients with multiple-site occlusive vascular disease. Cerebrovasc Dis. 2011;31:315321.
  • 25
    Van Kuijk JP, Flu WJ, Galal W, et al. The influence of polyvascular disease on the obesity paradox in vascular surgery patients. J Vasc Surg. 2011;53:399406.
  • 26
    Van Kuijk JP, Flu WJ, Welten GM, et al. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. Eur Heart J. 2010;31:992999.
  • 27
    Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170:10241031.
  • 28
    De Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170:10321036.
  • 29
    Hernández-Hernández R, Silva H, Velasco M, et al. Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study. J Hypertens. 2010;28:2434.
  • 30
    Baños-González M, Cantú-Brito C, Chiquete E, et al. Systolic blood pressure and functional outcome in patients with acute stroke: a Mexican registry of acute cerebrovascular disease (RENAMEVASC) [article in Spanish]. Arch Cardiol Mex. 2011;81:169175.
  • 31
    Dallongeville J, Bhatt DL, Steg PG, et al. Relation between body mass index, waist circumference, and cardiovascular outcomes in 19 579 diabetic patients with established vascular disease: the REACH Registry. Eur J Cardiovasc Prev Rehabil. 2012;19:241249.
  • 32
    Chiquete E, Cantú-Brito C, Villarreal-Careaga J, et al. Obesity paradox and functional recovery in first-ever acute ischemic stroke survivors: the PREMIER study [article in Spanish]. Rev Neurol. 2010;51:705713.
  • 33
    Adamopoulos C, Meyer P, Desai RV, et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail. 2011;13:200206.
  • 34
    Myers J, Lata K, Chowdhury S, et al. The obesity paradox and weight loss. Am J Med. 2011;124:924930.
  • 35
    Whitlock G, Lewington S, et al; Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:10831096.
  • 36
    Margolis JR, Gillum RF, Feinleib M, et al. Community surveillance for coronary heart disease: the Framingham Cardiovascular Disease survey. Comparisons with the Framingham Heart Study and previous short-term studies. Am J Cardiol. 1976;37:6167.
  • 37
    Wilson PW, Nam BH, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005;165:24732478.
  • 38
    Rautio A, Lundberg V, Messner T, et al. Favourable trends in the incidence and outcome of myocardial infarction in nondiabetic, but not in diabetic, subjects: findings from the MONICA myocardial infarction registry in northern Sweden in 1989–2000. J Intern Med. 2005;258:369377.